<DOC>
	<DOCNO>NCT01615029</DOCNO>
	<brief_summary>The purpose study establish safety profile daratumumab give combination Lenalidomide dexamethasone participant relapse relapsed refractory Multiple Myeloma ( MM ) .</brief_summary>
	<brief_title>Daratumumab Combination With Lenalidomide Dexamethasone Relapsed Relapsed-refractory Multiple Myeloma</brief_title>
	<detailed_description>The study conduct two part . The dose escalation portion trial ( Part 1 ) participant enrol cohort increase dose level daratumumab combination Len/Dex 28 day treatment cycle . Part 2 , cohort expansion part trial , explore maximum tolerate dose ( MTD ) ( maximum test dose ) daratumumab determine Part 1 .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>( Part 1 ) Have relapse multiple myeloma receive minimum 2 maximum 4 prior line therapy eligible treatment lenalidomide dexamethasone ( Len/Dex ) ( Part 2 ) Have receive least 1 prior line therapy multiple myeloma Be old 18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status ( 02 ) Provide sign informed consent receipt oral write information study studyrelated activity perform Have previously receive allogenic stem cell transplant Have receive autologous stem cell transplant within 12 week first infusion Have receive antimyeloma treatment , radiotherapy , experimental drug therapy within 2 week first infusion Have discontinue lenalidomide due treatmentrelated adverse event refractory dose lenalidomide . Refractory lenalidomide define either , participant whose disease progress within 60 day lenalidomide , participant whose disease nonresponsive dose lenalidomide . Nonresponsive disease define either failure achieve least minimal response ( MR ) development progressive disease ( PD ) lenalidomide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Daratumumab</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Dose-escalation</keyword>
	<keyword>Relapsed multiple myeloma</keyword>
	<keyword>Relapsed refractory multiple myeloma</keyword>
</DOC>